THE ADVI ANGLE

Resources and insights to help you keep up with policy and market trends in a transforming healthcare ecosystem

Showing In the Press

ADVI Director, Lindsay Bealor Greenleaf, discussed why including a drug’s list price in direct-to-consumer ads can be misleading to patients with The Daily Caller

“Simply disclosing a drug’s list price in advertisements can be misleading because list prices don’t reflect patients’ out-of-pocket costs, which vary from plan to plan,” Lindsay Bealor Greenleaf, Director of Policy at ADVI Health, told The Daily Caller News Foundation in a statement Friday.

Read more

ADVI VP Michael Kolodziej discussed creating new alternative payment models for emerging novel therapies at ASCO’s annual meeting with Pink Sheet

ADVI Vice President, Michael Kolodziej, discussed creating new alternative payment models for emerging novel therapies at the American Society for Clinical Oncology’s annual meeting with Pink Sheet.

Read more

ADVI Director Becca Davison discussed with Bloomberg Law the Senate’s HELP Committee’s latest draft bill aimed at reducing health care costs and how it would impact pharmacy benefit managers

Last week, the Senate HELP Committee released a bipartisan discussion draft aimed at reducing health care costs. The bill focused on the role that PBMs play in driving up the cost of drugs and included a provision which would ban the practice of “spread pricing,” a tactic PBMs use that allows them to pocket the difference between the price they charge a pharmacy and the wholesale price they pay to the drug manufacturer. This is yet another move by lawmakers and regulators to focus on the role that rebates and PBMs are playing in the drug supply chain.

Read more

Lindsay Bealor Greenleaf talks to the Daily Caller about new drug price transparency requirements for TV ads

“List prices don’t account for the rebates and negotiated discounts—which totaled $166 billion in 2018 —that are provided to pharmacy benefits managers and other players in the supply chain, plus patients’ out-of-pocket costs vary from plan to plan,” Lindsay Bealor Greenleaf, Director of Policy at ADVI Health, told The Daily Caller News Foundation in a statement Wednesday. “It’s great that the administration has taken steps with a separate pending regulation to address the supply chain distortions caused by rebates paid to pharmacy benefit managers,” Bealor Greenleaf continued. “However, requiring list price disclosure in advertisements before the market has a chance to respond to pending rebate changes is premature and will confuse patients about a treatment’s affordability.”

Read more